Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P B Sugerman

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Archives of Oral Biology|July 13, 1999
Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planusC Simark-Mattsson, G Bergenholtz, M Jontell, et al.
Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists|August 23, 2002
The pathogenesis of oral lichen planusP B Sugerman, N W Savage, L J Walsh, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgarisD F Murrell, A Patsatsi, P Stavropoulos, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Archives of Oral Biology|July 13, 1999
Distribution of interleukin-2, -4, -10, tumour necrosis factor-alpha and transforming growth factor-beta mRNAs in oral lichen planusC Simark-Mattsson, G Bergenholtz, M Jontell, et al.
Critical Reviews in Oral Biology and Medicine : an Official Publication of the American Association of Oral Biologists|August 23, 2002
The pathogenesis of oral lichen planusP B Sugerman, N W Savage, L J Walsh, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 10, 2022
Phase 2 BELIEVE study part B: Efficacy and safety of rilzabrutinib for patients with pemphigus vulgarisD F Murrell, A Patsatsi, P Stavropoulos, et al.
Pageof 4